Cisen Pharmaceutical Co Ltd - Asset Resilience Ratio
Cisen Pharmaceutical Co Ltd (603367) has an Asset Resilience Ratio of 30.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Cisen Pharmaceutical Co Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Cisen Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Cisen Pharmaceutical Co Ltd's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Cisen Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Cisen Pharmaceutical Co Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.35 Billion | 30.69% |
| Total Liquid Assets | CN¥2.35 Billion | 30.69% |
Asset Resilience Insights
- Very High Liquidity: Cisen Pharmaceutical Co Ltd maintains exceptional liquid asset reserves at 30.69% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cisen Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Cisen Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Cisen Pharmaceutical Co Ltd (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Cisen Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 22.77% | CN¥1.73 Billion ≈ $253.13 Million |
CN¥7.60 Billion ≈ $1.11 Billion |
+5.89pp |
| 2024-12-31 | 16.88% | CN¥1.28 Billion ≈ $186.58 Million |
CN¥7.55 Billion ≈ $1.11 Billion |
-5.44pp |
| 2023-12-31 | 22.32% | CN¥1.64 Billion ≈ $239.64 Million |
CN¥7.34 Billion ≈ $1.07 Billion |
-0.42pp |
| 2022-12-31 | 22.74% | CN¥1.55 Billion ≈ $226.77 Million |
CN¥6.82 Billion ≈ $997.26 Million |
-0.59pp |
| 2021-12-31 | 23.33% | CN¥1.48 Billion ≈ $217.25 Million |
CN¥6.36 Billion ≈ $931.21 Million |
-7.08pp |
| 2020-12-31 | 30.41% | CN¥1.88 Billion ≈ $274.41 Million |
CN¥6.17 Billion ≈ $902.24 Million |
-5.30pp |
| 2019-12-31 | 35.72% | CN¥1.98 Billion ≈ $289.24 Million |
CN¥5.53 Billion ≈ $809.76 Million |
+35.45pp |
| 2018-12-31 | 0.27% | CN¥14.33 Million ≈ $2.10 Million |
CN¥5.25 Billion ≈ $768.00 Million |
-0.15pp |
| 2017-12-31 | 0.42% | CN¥20.00 Million ≈ $2.93 Million |
CN¥4.74 Billion ≈ $693.89 Million |
-3.24pp |
| 2016-12-31 | 3.66% | CN¥120.00 Million ≈ $17.56 Million |
CN¥3.28 Billion ≈ $480.08 Million |
+1.68pp |
| 2015-12-31 | 1.98% | CN¥60.00 Million ≈ $8.78 Million |
CN¥3.03 Billion ≈ $443.97 Million |
-- |
About Cisen Pharmaceutical Co Ltd
Cisen Pharmaceutical Co., Ltd., together with its subsidiaries, research, develops, produces, and sells drug products. The company's chemical preparations include basic infusion, therapeutic infusion, liver disease medication, nervous system drugs, anti-tumor and adjuvant drugs, nutritional infusion, contrast agents, cardiovascular and cerebrovascular drugs, anti-infective drugs, anesthetic and a… Read more